Second-Line Treatment Options in Advanced Prostate Cancer

Robert Dreicer, MD, provides an overview of advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and available and emerging second-line treatment options for mCRPC.

EP1: First-Line Therapy Options in Metastatic Castration-Resistant Prostate Cancer

January 21st 2022

Robert Dreicer, MD, provides an overview of the first-line therapy options available in metastatic castration-resistant prostate cancer and the recent advances in detection, diagnosis, and treatment.

EP2: Second-Line Therapy Options in Metastatic Castration-Resistant Prostate Cancer

January 21st 2022

Robert Dreicer, MD, discusses the available second-line therapy options and unmet needs in metastatic castration-resistant prostate cancer.

EP3: Sabizabulin for Metastatic Castration-Resistant Prostate Cancer

January 28th 2022

A prostate cancer expert explains the potential advantages of sabizabulin, a new treatment for metastatic castration-resistant prostate cancer currently in a phase III clinical trial.

EP4: Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer

January 28th 2022

Robert Dreicer, MD, describes the future of metastatic castration-resistant prostate cancer.